{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T17:09:36Z","timestamp":1778432976445,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,10]]},"DOI":"10.7759\/cureus.108595","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T16:54:41Z","timestamp":1778432081000},"source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Management of Post-traumatic Brain Injury Bipolar-Spectrum Disorder With Low-Dose Oral Glutamatergic Augmentation: Extended Follow-Up Revealing Induction, Overshoot, Stabilization, and Transition to PRN Maintenance"],"prefix":"10.7759","author":[{"given":"Ngo","family":"Cheung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13020190","article-title":"Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury","volume":"171","author":"Orlovska S","year":"2014","unstructured":"Orlovska S, Pedersen MS, Benros ME, Mortensen PB, Agerbo E, Nordentoft M. Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury. Am J Psychiatry. 2014, 171:463-9. 10.1176\/appi.ajp.2013.13020190","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.11.035","article-title":"Traumatic brain injury and affective disorder: a nationwide cohort study in Taiwan, 2000-2010","volume":"191","author":"Chi YC","year":"2016","unstructured":"Chi YC, Wu HL, Chu CP, Huang MC, Lee PC, Chen YY. Traumatic brain injury and affective disorder: a nationwide cohort study in Taiwan, 2000-2010. J Affect Disord. 2016, 191:56-61. 10.1016\/j.jad.2015.11.035","journal-title":"J Affect Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2013.11.005","article-title":"Mood disorders after TBI","volume":"37","author":"Jorge RE","year":"2014","unstructured":"Jorge RE, Arciniegas DB. Mood disorders after TBI. Psychiatr Clin N Am. 2014, 37:13-29. 10.1016\/j.psc.2013.11.005","journal-title":"Psychiatr Clin N Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-018-0128-6","article-title":"Clinical characteristics of patients with bipolar disorder and premorbid traumatic brain injury: a cross-sectional study","volume":"6","author":"Drange OK","year":"2018","unstructured":"Drange OK, Vaaler AE, Morken G, Andreassen OA, Malt UF, Finseth PI. Clinical characteristics of patients with bipolar disorder and premorbid traumatic brain injury: a cross-sectional study. Int J Bipolar Disord. 2018, 6:19. 10.1186\/s40345-018-0128-6","journal-title":"Int J Bipolar Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li N","year":"2010","unstructured":"Li N, Lee B, Liu RJ, et al.. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010, 329:959-64. 10.1126\/science.1190287","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos P","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, et al.. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016, 533:481-6. 10.1038\/nature17998","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate CA Jr","year":"2012","unstructured":"Zarate CA Jr, Brutsche NE, Ibrahim L, et al.. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012, 71:939-46. 10.1016\/j.biopsych.2011.12.010","journal-title":"Biol Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora G","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W, et al.. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017, 74:399-405. 10.1001\/jamapsychiatry.2017.0080","journal-title":"JAMA Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05, dextromethorphan-bupropion, in patients with major depressive disorder: a phase 3 randomized clinical trial, GEMINI","volume":"83","author":"Iosifescu DV","year":"2022","unstructured":"Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Efficacy and safety of AXS-05, dextromethorphan-bupropion, in patients with major depressive disorder: a phase 3 randomized clinical trial, GEMINI. J Clin Psychiatry. 2022, 83:21m14345. 10.4088\/JCP.21m14345","journal-title":"J Clin Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings JL","year":"2015","unstructured":"Cummings JL, Lyketsos CG, Peskind ER, et al.. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015, 314:1242-54. 10.1001\/jama.2015.10214","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.25cr16262","article-title":"Oral glutamatergic modulation with dextromethorphan and piracetam for refractory bipolar disorder with obsessive-compulsive disorder: three consecutive cases from routine practice","volume":"87","author":"Cheung N","year":"2026","unstructured":"Cheung N. Oral glutamatergic modulation with dextromethorphan and piracetam for refractory bipolar disorder with obsessive-compulsive disorder: three consecutive cases from routine practice. J Clin Psychiatry. 2026, 87:25cr16262. 10.4088\/JCP.25cr16262","journal-title":"J Clin Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/25424823261433953","article-title":"The Cheung Glutamatergic Regimen as a candidate for primary and secondary prevention of Alzheimer's disease onset","volume":"10","author":"Cheung N","year":"2026","unstructured":"Cheung N. The Cheung Glutamatergic Regimen as a candidate for primary and secondary prevention of Alzheimer's disease onset. J Alzheimer's Dis Rep. 2026, 10:25424823261433953. 10.1177\/25424823261433953","journal-title":"J Alzheimer's Dis Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.2246.v1","article-title":"Clinical experience and optimisation of the Cheung Glutamatergic Regimen for refractory psychiatric diseases","author":"Cheung N","year":"2025","unstructured":"Cheung N. Clinical experience and optimisation of the Cheung Glutamatergic Regimen for refractory psychiatric diseases. 2025, 10.20944\/preprints202511.2246.v1"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.32067252.v1","article-title":"Disorder-specific mitochondrial, telomere, and plasticity signatures revealed by cross-disorder TWAS in OCD, MDD, and bipolar disorder","author":"Cheung N","year":"2026","unstructured":"Cheung N. Disorder-specific mitochondrial, telomere, and plasticity signatures revealed by cross-disorder TWAS in OCD, MDD, and bipolar disorder. 2026, 10.6084\/m9.figshare.32067252.v1"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001, 16:606-13. 10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer RL","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006, 166:1092-7. 10.1001\/archinte.166.10.1092","journal-title":"Arch Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200701000-00002","article-title":"The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline","volume":"13","author":"Preskorn SH","year":"2007","unstructured":"Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract. 2007, 13:5-12. 10.1097\/00131746-200701000-00002","journal-title":"J Psychiatr Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young RC","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA.  A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978, 133:429-35. 10.1192\/bjp.133.5.429","journal-title":"Br J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491220-longitudinal-management-of-post-traumatic-brain-injury-bipolar-spectrum-disorder-with-low-dose-oral-glutamatergic-augmentation-extended-follow-up-revealing-induction-overshoot-stabilization-and-transition-to-prn-maintenance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T16:54:42Z","timestamp":1778432082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491220-longitudinal-management-of-post-traumatic-brain-injury-bipolar-spectrum-disorder-with-low-dose-oral-glutamatergic-augmentation-extended-follow-up-revealing-induction-overshoot-stabilization-and-transition-to-prn-maintenance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.108595","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}